

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Rachael ANCLIFF et al.

Application. No.: 10/531,758

Filing Date: 4/14/2005

Title: Substituted Piperazines (1,4) Diaszepines, and 2,5-Diazabicyclo (2.2.1) Heptanes as Histamine H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists

Attorney Docket No.: P33126USw

Examiner: COLEMAN, Brenda Libby

Art unit: 1624

Confirmation No.: 5647

---

**COMMISSIONER FOR PATENTS**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**Response to Restriction Requirement**

Sir:

The following is in response to the restriction requirement dated December 3, 2007 for which a one month period for response was designated. As this submission is timely filed by January 3, 2008, applicant does not believe any fee is due. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment associated with this application to Deposit Account No. 07-1392.

Please amend the attached application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begin on page 2.

**Remarks** begin on page .